SuperworthAccendra Health EPS ACH
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- −$3.92
- Latest quarter, Q2 FY26
- −$1.16
- Fiscal year 2025
- −$14.30
Accendra Health's earnings per share was −$3.92 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$1.16.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$14.30 | n/a |
| FY2024 | −$4.72 | n/a |
| FY2023 | −$0.54 | −293% |
| FY2022 | $0.28 | −91% |
| FY2021 | $2.98 | +684% |
| FY2020 | $0.38 | n/a |
| FY2019 | −$1.02 | n/a |
| FY2018 | −$7.31 | −709% |
| FY2017 | $1.20 | −32% |
| FY2016 | $1.77 | +7% |
| FY2015 | $1.65 | +56% |
| FY2014 | $1.06 | −39% |
| FY2013 | $1.75 | +2% |
| FY2012 | $1.72 | −5% |
| FY2011 | $1.82 | +4% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.16 | n/a | −$3.92 | |
| Q1 FY26 | −$0.08 | n/a | −$14.06 | |
| Q4 FY25 | −$0.74 | n/a | −$14.30 | |
| Q3 FY25 | −$1.94 | n/a | −$17.41 | |
| Q2 FY25 | −$11.30 | n/a | −$15.63 | |
| Q1 FY25 | −$0.32 | n/a | −$4.75 | |
| Q4 FY24 | −$3.85 | −1774% | −$4.72 | |
| Q3 FY24 | −$0.16 | n/a | −$0.64 | |
| Q2 FY24 | −$0.42 | n/a | −$0.56 | |
| Q1 FY24 | −$0.29 | n/a | −$0.51 | |
| Q4 FY23 | $0.23 | n/a | −$0.54 | |
| Q3 FY23 | −$0.08 | −150% | −$1.54 |
Against its peers
Companies in Healthcare nearest Accendra Health's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ACHAccendra Health | −$3.92 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| ICCCImmucell | $0.08 | −58% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Accendra Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.